Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus - Related Burkitt's lymphoma

Molecular Cancer Therapeutics

Volumn 10, Issue 4, 2011, Pages 679-686

  Cen, Osman ^a   Longnecker, Richard ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; BONE MARROW; BURKITT LYMPHOMA; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; EPSTEIN BARR VIRUS; GENE FUNCTION; IMMUNOGLOBULIN GENE; LATENT PERIOD; METASTASIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; SPLENOMEGALY; TRANSGENIC MOUSE; TRANSGENICS; TUMOR CELL; TUMOR GROWTH; VIRUS GENE;

ANIMALS; APOPTOSIS; BURKITT LYMPHOMA; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HOMEODOMAIN PROTEINS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; SIROLIMUS; SPLENOMEGALY; TUMOR BURDEN; VIRAL MATRIX PROTEINS;

EID: 79953049807     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0833     Document Type: Article

References (50)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. Fields Virology. 5 ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2655-700.
2. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-37. (Pubitemid 38375368)
3. Merchant M, Caldwell RG, Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 2000;74:9115-24.
4. Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A. Cell Cycle 2010;9:901-8.
5. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998;9:405-11. (Pubitemid 28462761)
6. Longnecker R, Merchant M, Brown ME, Fruehling S, Bickford JO, Ikeda M, et al. WW- and SH3-domain interactions with Epstein-Barr virus LMP2A. Exp Cell Res 2000;257:332-40. (Pubitemid 30390484)
7. Ikeda M, Ikeda A, Longnecker R. Lysine-independent ubiquitination of Epstein-Barr virus LMP2A. Virology 2002;300:153-9.
8. Ikeda M, Longnecker R. The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. Virology 2009;385:183-91.
9. Winberg G, Matskova L, Chen F, Plant P, Rotin D, Gish G, et al. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol Cell Biol 2000;20:8526-35.
10. Fruehling S, Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 1997;235:241-51. (Pubitemid 27394337)
11. Fruehling S, Swart R, Dolwick KM, Kremmer E, Longnecker R. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol 1998;72:7796-806. (Pubitemid 28421769)
12. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 2006;87:2885-90. (Pubitemid 44463896)
13. Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, Kazembe P, et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 2002;99:635-43. (Pubitemid 34538741)
14. Ong KW, Teo M, Lee V, Ong D, Lee A, Tan CS, et al. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res 2009;15:5350-8.
15. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. Epstein- Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998;91:1373-81. (Pubitemid 28086891)
16. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990;55:133-270. (Pubitemid 20259302)
17. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, et al. Burkitt lymphoma in the mouse. J Exp Med 2000;192:1183-90.
18. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8. (Pubitemid 16173038)
19. Bieging KT, Amick AC, Longnecker R. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci U S A 2009;106:17945-50.
20. Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 2009;28:1471-6.
21. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008;13:563-8.
22. Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol 2007;81:9299-306.
23. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates Blymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 2004;23:8619-28. (Pubitemid 39576469)
24. Fukuda M, Longnecker R. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 2004;78:1697-705. (Pubitemid 38176702)
25. Swart R, Ruf IK, Sample J, Longnecker R. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol 2000;74:10838-45.
26. Morrison JA, Klingelhutz AJ, Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 2003;77:12276-84. (Pubitemid 37339880)
27. Moody CA, Scott RS, Amirghahari N, Nathan CO, Young LS, Dawson CW, et al. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 2005;79:5499-506. (Pubitemid 40548218)
28. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007;83:1114-21. (Pubitemid 46659124)
29. Caldwell RG, Brown RC, Longnecker R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 2000;74:1101-13. (Pubitemid 30044059)
30. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006;66:7639-46. (Pubitemid 44289221)
31. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;68:869-77.
32. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, et al. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 2008;14:5416-25.
33. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003;63:4472-80. (Pubitemid 36951019)
34. Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem Biophys Res Commun 1997;230:386-91. (Pubitemid 27212007)
35. Johnson KL, Lawen A. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. Immunol Cell Biol 1999;77:242-8. (Pubitemid 29251577)
36. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010;115:4455-63.
37. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-51. (Pubitemid 47222041)
38. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010;28:275-80.
39. Fukuda M, Longnecker R. Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol 2005;79:8655-60. (Pubitemid 40853566)
40. Holtan SG, Porrata LF, Colgan JP, Zent CS, Habermann TM, Markovic SN. mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD). Am J Hematol 2008;83:688-9.
41. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8. (Pubitemid 41161231)
42. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101. (Pubitemid 40262113)
43. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302. (Pubitemid 38991819)
44. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15:148-59.
45. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-8. (Pubitemid 39468014)
46. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-61. (Pubitemid 41080576)
47. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-61.
48. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e38.
49. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
50. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32.